News
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market ...
Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
Pharmaceutical Technology on MSN4d
Novo Nordisk defeated in Wegovy patent dispute by ViatrisThe Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...
Zacks Investment Research on MSN5d
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback